Literature DB >> 26872818

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.

Patrick Micke1, Johanna Sofia Margareta Mattsson1, Dijana Djureinovic1, Björn Nodin2, Karin Jirström3, Lena Tran4, Per Jönsson5, Maria Planck6, Johan Botling1, Hans Brunnström7.   

Abstract

INTRODUCTION: Histopathological classification of lung cancer is of central importance in the diagnostic routine, and it guides therapy in most patients. The fourth edition of the World Health Organization (WHO) Classification of Lung Tumours was recently published and includes changes to the diagnostic procedure for non-small cell carcinomas (NSCCs), with more emphasis on immunohistochemical (IHC) staining.
METHODS: A total of 656 unselective cases of resected pulmonary NSCC were diagnosed according to the 2004 WHO classification. After IHC staining with cytokeratin 5, p40, p63, thyroid transcription factor 1 (clones 8G7G3/1 and SPT24), and napsin A, the diagnoses were revised in accordance with the new fourth edition of the WHO classification.
RESULTS: Reclassification led to a new histological annotation in 36 of the 656 cases (5%). Most notable was the decrease in cases previously classified as large cell carcinomas (56 versus 12 cases). This was partially due to the exclusion of 21 neuroendocrine tumors from this group, with 20 cases ascribed to the adenocarcinoma group on the basis of IHC markers. Only seven cases of adenocarcinoma or squamous cell carcinoma were reclassified after the addition of IHC staining. There was a substantial overlap in staining properties between different markers of squamous and adenocarcinomatous differentiation, respectively, but in 17 to 31 cases (3%-5%), the diagnosis depended on the choice of markers.
CONCLUSIONS: The fourth edition of the WHO Classification of Lung Tumours leads to changes in histological type in 5% of resected NSCCs. The incorporation of IHC staining into NSCC diagnostics demands awareness that the choice of ancillary stains has an effect on diagnosis.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung cancer; NSCC; Pathology; TTF-1; p40

Mesh:

Substances:

Year:  2016        PMID: 26872818     DOI: 10.1016/j.jtho.2016.01.020

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  24 in total

1.  PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.

Authors:  Hans Brunnström; Anna Johansson; Sofia Westbom-Fremer; Max Backman; Dijana Djureinovic; Annika Patthey; Martin Isaksson-Mettävainio; Miklos Gulyas; Patrick Micke
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

2.  Curcumin inhibits the development of non-small cell lung cancer by inhibiting autophagy and apoptosis.

Authors:  Aili Wang; Jinxiang Wang; Shuming Zhang; Hongxia Zhang; Zhenyang Xu; Xiaohui Li
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

3.  The value of cell block based on fine needle aspiration for lung cancer diagnosis.

Authors:  Zhengwei Dong; Hui Li; Jun Zhou; Wei Zhang; Chunyan Wu
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Genome-wide copy number variation pattern analysis and a classification signature for non-small cell lung cancer.

Authors:  Zhe-Wei Qiu; Jia-Hao Bi; Adi F Gazdar; Kai Song
Journal:  Genes Chromosomes Cancer       Date:  2017-05-04       Impact factor: 5.006

5.  The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Bo Pan; Zi-Xin Wei; Ju-Xuan Zhang; Xin Li; Qing-Wei Meng; Ying-Yue Cao; Li-Shuang Qi; Yan Yu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

6.  Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.

Authors:  Marianna Grinberg; Dijana Djureinovic; Hans Rr Brunnström; Johanna Sm Mattsson; Karolina Edlund; Jan G Hengstler; Linnea La Fleur; Simon Ekman; Hirsh Koyi; Eva Branden; Elisabeth Ståhle; Karin Jirström; Derek K Tracy; Fredrik Pontén; Johan Botling; Jörg Rahnenführer; Patrick Micke
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

7.  Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer.

Authors:  Johanna S M Mattsson; Hans Brunnström; Verena Jabs; Karolina Edlund; Karin Jirström; Stephanie Mindus; Linnéa la Fleur; Fredrik Pontén; Mats G Karlsson; Christina Karlsson; Hirsh Koyi; Eva Brandén; Johan Botling; Gisela Helenius; Patrick Micke; Maria A Svensson
Journal:  BMC Cancer       Date:  2016-08-05       Impact factor: 4.430

8.  An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.

Authors:  Wen-E Wei; Nai-Quan Mao; Shu-Fang Ning; Ji-Lin Li; Hai-Zhou Liu; Tong Xie; Jian-Hong Zhong; Yan Feng; Chang-Hong Wei; Li-Tu Zhang
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

9.  Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study.

Authors:  Renwang Liu; Jinghao Liu; Tao Shi; Xiongfei Li; Dian Ren; Gang Chen; Ying Li; Hongyu Liu; Song Xu; Jun Chen
Journal:  Oncotarget       Date:  2017-10-11

10.  Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma.

Authors:  Changjiang Feng; Jiaqi Wu; Fan Yang; Mangtang Qiu; Shuofeng Hu; Saisai Guo; Jin Wu; Xiaomin Ying; Jun Wang
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.